The Dominance of the US Pharmaceutical Market
The pharmaceutical market in the United States generates billions and plays a major role in the global pharmaceutical industry. As the world's largest pharma market, it accounts for a significant share of global revenues for leading brands. According to the Statista report, "Top pharmaceutical drugs," published in December 2025, the highest-grossing drugs in the U.S. concentrated tens of billions of dollars in sales, mainly driven by treatments for cancer, diabetes, and autoimmune diseases.
This best-selling drugs in the US 2024 ranking serves as a key indicator of industry trends, highlighting blockbuster medications that sustain high sales volumes within U.S. territory. The dynamism of this market influences drug pricing, innovation, and access worldwide, making it essential for patients, providers, and investors to understand these leaders.
Keytruda Tops the 2024 US Sales Charts
According to data compiled by Statista, the drug with the highest revenue in the United States in 2024 was Keytruda (Merck & Co.), with approximately 17.87 billion U.S. dollars in sales. Keytruda is an oncology treatment based on immunotherapy used for various types of cancer, including lung cancer, melanoma, and lymphomas.
How Keytruda Works: Mechanism of Action
Keytruda, or pembrolizumab, is a PD-1 inhibitor that harnesses the body's immune system to fight cancer cells. By blocking the PD-1 protein on T-cells, it prevents tumors from evading immune detection, leading to more effective tumor destruction. This immunotherapy approach has revolutionized treatment for advanced cancers, contributing to its leadership in sales.
Why Keytruda Reflects Oncology Market Growth
Its leadership reflects the sustained growth of the cancer drug market, which also leads therapeutic areas by revenue in the United States. Oncology's dominance responds to several factors, including aging populations, rising cancer incidence, and breakthroughs in precision medicine. Immunotherapy has become one of the pillars of the pharmaceutical industry, driving multibillion-dollar revenues and positioning certain brands as global leaders.
For patients with eligible cancers, Keytruda offers improved survival rates, but discussions with oncologists are crucial to assess suitability, potential immune-related side effects like colitis or pneumonitis, and combination therapies.
Top 10 Best-Selling Drugs in the US for 2024
The Statista report outlines the top 10 drugs by sales in the United States in 2024. This ranking highlights the dominance of biologic treatments and innovative therapies aimed at complex and chronic diseases. While Keytruda secures the #1 spot, the list features other heavyweights in oncology, diabetes, and autoimmune categories, underscoring a focus on high-need areas.
- Oncology leaders like Keytruda set the pace with immunotherapy innovations.
- Diabetes treatments such as Ozempic and Mounjaro gain traction amid rising metabolic health demands.
- Autoimmune drugs like Dupixent address inflammatory conditions effectively.
These top-sellers exemplify how biologics—large-molecule drugs produced via biotech processes—outpace small-molecule alternatives due to their targeted efficacy and patent protections.
Precision tracking for your journey
Join thousands using Shotlee to accurately track GLP-1 medications and side effects.
📱 Get the Shotlee App
Track your GLP-1 medications, peptides, and health metrics on the go with our mobile app!
Therapeutic Areas Leading US Pharma Revenues in 2025
The Statista report shows that the therapeutic areas generating the highest revenues in the United States in 2025 are led by oncology. This explains why drugs such as Keytruda (cancer), Ozempic and Mounjaro (type 2 diabetes), or Dupixent (inflammatory diseases) dominate sales statistics.
Oncology: The Revenue King
Oncology holds the top position due to high treatment costs, chronic nature of cancers, and expanding indications for immunotherapies. Patients benefit from longer remission periods, but managing side effects like fatigue or rash requires vigilant monitoring.
Diabetes and Metabolic Health: Rise of GLP-1s
Type 2 diabetes treatments like Ozempic (semaglutide) and Mounjaro (tirzepatide) are climbing ranks. These GLP-1 receptor agonists (Ozempic) and dual GLP-1/GIP agonists (Mounjaro) mimic gut hormones to regulate blood sugar, promote weight loss, and reduce cardiovascular risks. For patients, they offer once-weekly dosing convenience, but gastrointestinal side effects like nausea are common initially. Tools like Shotlee can help track symptoms, side effects, or medication schedules for better adherence.
Compared to older diabetes drugs like metformin, GLP-1s provide superior A1C reduction and heart protection, driving their sales surge.
Autoimmune and Inflammatory Diseases: Dupixent's Role
Dupixent (dupilumab), an IL-4/IL-13 inhibitor, targets eczema, asthma, and nasal polyps by modulating immune responses. Its biologic nature supports long-term control, with sales boosted by expanded approvals. Safety profiles include injection-site reactions, but it outperforms steroids for many.
Factors Fueling These Blockbuster Sales
Beyond innovation, US sales are propelled by strong reimbursement, direct-to-consumer advertising, and unmet needs in chronic diseases. The market's scale impacts global R&D, as US revenues fund pipelines for new therapies. For patients, this means more options but also higher costs—discussing generics or assistance programs with doctors is key.
Global Implications of US Drug Sales Trends
The United States represents a significant share of global revenues for leading brands. Many blockbuster drug figures worldwide are sustained by sales volumes within U.S. territory. The dynamism of the U.S. market also impacts drug development pipelines, pricing strategies, and access in other regions. For this reason, the U.S. sales ranking serves as a key thermometer for understanding where the global pharmaceutical industry is heading.
Key Takeaways for Patients and Healthcare Providers
- Keytruda's $17.87B sales highlight immunotherapy's role in cancer care—consult specialists for PD-1 eligibility.
- GLP-1 drugs like Ozempic and Mounjaro excel in diabetes management; monitor for GI effects and heart benefits.
- Oncology leads revenues, but diabetes and autoimmune therapies are fast-growers.
- Biologics dominate due to efficacy in complex diseases.
- Discuss personalized risks/benefits with providers; track progress with apps like Shotlee.
Conclusion: Navigating the Future of US Pharma Leaders
The 2024 best-selling drugs ranking, per Statista, reveals a landscape shaped by oncology innovators like Keytruda and rising stars in diabetes like Ozempic and Mounjaro. Patients should leverage these advances by partnering with healthcare teams for optimal outcomes. Stay informed on sales trends to anticipate shifts in treatment availability and costs.
